Page 4 - Sci Partners News Today : Breaking News, Live Updates & Top Stories | Vimarsana

62% vs. 25% overall response rates with navicixizumab plus paclitaxel in biomarker positive vs. biomarker negative patients using the Xerna™ TME Panel ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. OncXerna Therapeutics Provides New Results from its Xerna™ RNA-based Biomarker Platform at the ... OncXerna Therapeutics, Inc.April 10, 2021 GMT Xerna™ TME Panel describes the tumor microenvironment based on dominant biology subtypes with prognostic capabilities in colorectal cancer Data supports the application of Xerna™ TME Panel beyond gastric and ovarian cancers for prospectively-driven trials with OncXerna’s clinical-stage programs WALTHAM, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- OncX...

OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs WALTHAM, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) — OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses to its first-in-class targeted oncology therapies, today announced the appointment of Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs. “I am thrilled to reunite with Colleen and have her join our team given her deep expertise in ...

Trevena, Inc. to Participate in Two Upcoming Virtual Investor Conferences CHESTERBROOK, Pa., Jan. 07, 2021 — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that management will participate in two upcoming virtual investor conferences, with additional details below.           About Trevena Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. T...